Biological Effects of p53 Mutation W248 and H175 on MCF-7 Cells

Abstract:

Objective: p53, a tumor suppressor gene, is one of the hotspots in the world of the biomedical field. Mutation of p53 gene, which is found in approximately 50% of human cancers, is a key event in carcinogenesis. This project aims to investigate the new characteristics of two p53 mutants, p53-W248 and p53-H175, in MCF-7 cells, so as to provide the experimental basis for understanding the functional alternations of mutant p53. Methods: In this study, MCF-7 cells transfected with p53-H175 or p53-W248 plasmids were used as experimental group and the MCF-7 cells transfected wild type p53 plasmid were used as control group. Then the biological effects at the cellular level were investigated using 3-(4.5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay, flow cytometry analysis and cell scratch test. Results: MTT assay showed that p53-W248 might promote cell proliferation in MCF-7 cells. The results of flow cytometry indicated that no significant effect on cell cycle progression and cell apoptosis by p53-H175 or p53-W248 in cells. The cell scratch test showed that p53-H175 could increase the ability of cell migration. Conclusion: p53-H175 could lead to the promotion of tumor cell migration, while p53-W248 may promote tumor cell proliferation. p53-H175 and p53-W248 might have acquired some new characteristics of oncogenes.

• Periodical: Advanced Materials Research (Volume 790)
• Pages: 550-554
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.790.550
• Online since: September 2013
• Authors: Xiang Yu Zhou, Ya Jun Liu, Dan Li
• Keywords: Cell Cycle, Cell Migration, Cell Proliferation, Mutation, p53-H175, p53-W248

References

[1] Lifang Yang, Weizhong Zeng, Dan Li and Rui Zhou. Inhibition of cell proliferation, migration and invasion by DNAzyme targeting MMP-9 in A549 cells. Oncology Report 22: 121-126, (2009).

DOI: 10.3892/or_00000414

[2] Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L, Benchimol S. Isolation and characterization of a human p.53 cDNA clone: expression of the human p.53 gene. EMBO J. 1984; 3(13): 3257–62.

DOI: 10.1002/j.1460-2075.1984.tb02287.x

[3] Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Localization of gene for human p.53 tumor antigen to band 17p13. Nature. 1986; 320 (6057): 84–5.

DOI: 10.1038/320084a0

[4] Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, and Vogelstein B. Identification of p.53 as a sequence-specific DNA-binding protein. Science. 1991; 252(5013): 1708–11.

DOI: 10.1126/science.2047879

[5] McBride OW, Merry D, Givol D. The gene for human p.53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc. Natl. Acad. Sci. U.S.A. 1986; 83 (1): 130–134.

DOI: 10.1073/pnas.83.1.130

[6] Koshland DE Jr. Molecular of the year. Science. 1993, 262: (1953).

[7] Minghua Zhu. Progress and significance of studies on biological functions of tumor suppressor gene p.53. Chinese Journal of Pathology. 2000; 29(1).

[8] Zacchi P, Gostissa M, Uchida T. The prolyl isomerase Pinl reveals a mechanism to control p.53 functions after genotoxic insults. 2002(6909).

DOI: 10.1038/nature01120

[9] Shaofeng Xu, Li Fu. Progress of p.53 gene. Chinese Journal of Pathology. 2004; 33(6).

[10] Siqian Lu, Shuting Jia, Ying Luo. Recent advances in mutant p.53 and novel personalized strategies for cancer therapy. Hereditas (Beijing). (2011).

DOI: 10.3724/sp.j.1005.2011.00539

[11] Sigal A, Rotter V. Oncogenic mutations of the p.53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 2000, 60(24): 6788−6793.

[12] Weisz L, Oren M, Rotter V. Transcription regulation by mutant p.53. Oncogene. 2007, 26(15): 2202−2211.

DOI: 10.1038/sj.onc.1210294

[13] Kastan MB, Berkovich E. p.53: a two-faced gene. Nat Cell Biol. 2007, 9(5): 489−491.

DOI: 10.1038/ncb0507-489